Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aegleio

- PMLiVE

Novo Nordisk: Strict US regulation threatens innovation

Warning from CEO Sorensen comes after Tresiba and Ryzodeg fail to win FDA approval

Boehringer Ingelheim and Lilly launch diabetes education campaign

Follows the partnership’s filing of its SGLT-2 inhibitor for European approval

- PMLiVE

Merck & Co enters $430m diabetes deal with Abide

Will target group of enzymes known as serine hydrolases

- PMLiVE

Sanofi launches diabetes drug Lyxumia in the UK

Says drug could make multimillion pound savings for the NHS

- PMLiVE

Merck & Co and Pfizer join forces on diabetes candidate

Latest big pharma alliance involving an SGLT2 inhibitor

- PMLiVE

Interview: Peter Meeus, Novo Nordisk

The managing director of Novo Nordisk UK discusses how education and new partnerships are helping fight the battle against the country’s worsening diabetes crisis

- PMLiVE

Boehringer: Tough HTA threatens future of German research

Drug pricing system is stifling innovation says pharma company

- PMLiVE

Novo Nordisk launches new US insulin campaign

US IndyCar driver, diabetic and FlexPen user Charlie Kimball fronts activities

- PMLiVE

Infographic: Type 2 diabetes in Brazil

Key facts about the chronic condition's impact in the emerging market

- PMLiVE

Brazil: Patient access and education in type 2 diabetes

As the prevalence of diabetes increases in Brazil, the healthcare system needs to respond 

- PMLiVE

Sanofi invests €20m in Morocco

Will also collaborate with government on diabetes, mental health, epilepsy and pharma training

- PMLiVE

Lilly to invest extra $180m in US insulin manufacturing

Response to growing demand for insulin pens for people with diabetes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links